B. Riley Turns Bullish on Capricor Before November Deramiocel Decision
B. Riley upgrades Capricor to Buy from Neutral and lifts its target to $21 from $5 ahead of the Nov. 22, 2026 deramiocel FDA date.
/ 1645 items
#XY↓
FDA Grants Breakthrough Therapy Designation to Armata’s Phage Therapy for Complicated Staph Blood Infections
FDA awards Breakthrough Therapy designation to Armata’s AP-SA02 for adjunct treatment of complicated staph bacteremia, including MRSA.
Definium Reports Third Phase 3 Win for Fast-Dissolve LSD Therapy
Definium’s DT120 ODT LSD tablet cut GAD anxiety scores 5.1 points vs placebo in Phase 3. Effects started by day 2. FDA filing targeted for 2027.
BioNTech Drug Nearly Doubles Survival in Hard-to-Treat Lung Cancer
Updated PRESERVE-003 data: gotistobart showed 18.5 vs 10 months median survival vs chemo in previously treated squamous NSCLC. Pivotal stage ongoing.
Ivonescimab Cuts Death Risk 27% vs Keytruda, With Strongest Gain in High PD-L1 Patients
HARMONi-2: Summit’s Ivonescimab extended median survival by 8.2 months vs Keytruda. 42% lower death risk in PD-L1-high patients.
Citi Calls Olema Drop After AstraZeneca Trial Miss a Buying Opportunity
Citi calls Olema’s drop after AstraZeneca’s SERENA-4 miss excessive, keeps Buy and $59 target, and sees $20 value from later-line use.